NCT01500083View on ClinicalTrials.gov

Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia

PHASE3CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Indolent Non-Hodgkin's LymphomaChronic Lymphocytic Leukemia
Interventions
DRUG

Bendamustine at a dose of 100 mg/m2

Bendamustine will be administered intravenously over 30 minutes.

DRUG

Bendamustine at a dose of 120 mg/m2

Bendamustine will be administered intravenous (i.v.) over 60 minutes.

Trial Locations (16)

T2N 4N2

CA015, Calgary

T6G 1Z2

CA014, Edmonton

V1Y 5L3

CA016, Kelowna

V5Z 4E6

CA011, Vancouver

V8R 6V5

CA013, Victoria

R3E 0V9

CA012, Winnipeg

B3H 2Y9

CA004, Halifax

L6R 3J7

CA009, Brampton

L8V 5C2

CA003, Hamilton

K1H 8L6

CA002, Ottawa

M5G 2M9

CA006, Toronto

N8W 2X3

CA005, Windsor

H2W 1S6

CA001, Montreal

H4J 1C5

CA010, Montreal

S7N 4H4

CA007, Saskatoon

G1J 1Z4

CA008, Québec

All Listed Sponsors
lead

Lundbeck Canada Inc.

INDUSTRY

NCT01500083 - Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter